Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis
Abstract Background Ulcerative colitis (UC) is a type of inflammatory bowel disease, and current treatments often fall short, necessitating new therapeutic options. Baicalin shows therapeutic promise in UC animal models, but a systematic review is needed. Methods A systematic search was conducted ac...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-03629-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862250733043712 |
|---|---|
| author | Jinchen Chong Zepeng Chen Jiaze Ma Linhai He Yijia Zhu Zhihua Lu Zhengxi Qiu Chen Chen Yugen Chen Feng Jiang |
| author_facet | Jinchen Chong Zepeng Chen Jiaze Ma Linhai He Yijia Zhu Zhihua Lu Zhengxi Qiu Chen Chen Yugen Chen Feng Jiang |
| author_sort | Jinchen Chong |
| collection | DOAJ |
| description | Abstract Background Ulcerative colitis (UC) is a type of inflammatory bowel disease, and current treatments often fall short, necessitating new therapeutic options. Baicalin shows therapeutic promise in UC animal models, but a systematic review is needed. Methods A systematic search was conducted across databases including PubMed, EBSCO, Web of Science, and Science Direct, up to March 2024, identifying randomized controlled trials (RCTs) examining baicalin’s impact on UC in animal models. Seventeen studies were selected through manual screening. Meta-analyses and subgroup analyses utilized Rev Man 5.3 and Stata 15.0 software to assess symptom improvement. Results From 1304 citations, 17 were analyzed. Baicalin significantly modulated various biomarkers: HCS (SMD = -3.91), DAI (MD = -2.75), spleen index (MD = -12.76), MDA (SMD = -3.88), IL-6 (SMD = -10.59), IL-1β (SMD = -3.98), TNF-α (SMD = -8.05), NF-κB (SMD = -5.46), TLR4 (MD = -0.38), RORγ (MD = -0.89), MCP-1 (MD = -153.25), MPO (SMD = -7.34), Caspase-9 (MD = -0.93), Caspase-3 (MD = -0.45), FasL (MD = -1.20)) and enhanced BWC (MD = 0.06), CL (MD = 1.39), ZO-1 (MD = 0.44), SOD (SMD = 3.04), IL-10 mRNA (MD = 3.14), and FOXP3 (MD = 0.45) levels. Baicalin’s actions may involve the PI3K/AKT, TLR4/NF-κB, IKK/IKB, Bcl-2/Bax, Th17/Treg, and TLRs/MyD88 pathways. Optimal therapeutic outcomes were predicted at dosages of 60–150 mg/kg over 10–14 weeks. Conclusion Baicalin demonstrates a multifaceted therapeutic potential in UC, attributed to its anti-inflammatory, antioxidant, anti-apoptotic, and intestinal barrier repair properties. While higher doses and longer treatments appear beneficial, further research, particularly human clinical trials, is necessary to verify its effectiveness and safety in people. |
| format | Article |
| id | doaj-art-e005dc0b914744f5a6450e4ff11d149a |
| institution | Kabale University |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-e005dc0b914744f5a6450e4ff11d149a2025-02-09T12:39:39ZengBMCBMC Gastroenterology1471-230X2025-02-0125112110.1186/s12876-025-03629-0Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysisJinchen Chong0Zepeng Chen1Jiaze Ma2Linhai He3Yijia Zhu4Zhihua Lu5Zhengxi Qiu6Chen Chen7Yugen Chen8Feng Jiang9The Affiliated Hospital of Nanjing University of Chinese MedicineShanghai University of Traditional Chinese MedicineThe Affiliated Hospital of Nanjing University of Chinese MedicineThe Affiliated Hospital of Nanjing University of Chinese MedicineThe Affiliated Hospital of Nanjing University of Chinese MedicineThe Affiliated Hospital of Nanjing University of Chinese MedicineThe Affiliated Hospital of Nanjing University of Chinese MedicineThe Affiliated Hospital of Nanjing University of Chinese MedicineDepartment of Colorectal Surgery, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese MedicineThe Affiliated Hospital of Nanjing University of Chinese MedicineAbstract Background Ulcerative colitis (UC) is a type of inflammatory bowel disease, and current treatments often fall short, necessitating new therapeutic options. Baicalin shows therapeutic promise in UC animal models, but a systematic review is needed. Methods A systematic search was conducted across databases including PubMed, EBSCO, Web of Science, and Science Direct, up to March 2024, identifying randomized controlled trials (RCTs) examining baicalin’s impact on UC in animal models. Seventeen studies were selected through manual screening. Meta-analyses and subgroup analyses utilized Rev Man 5.3 and Stata 15.0 software to assess symptom improvement. Results From 1304 citations, 17 were analyzed. Baicalin significantly modulated various biomarkers: HCS (SMD = -3.91), DAI (MD = -2.75), spleen index (MD = -12.76), MDA (SMD = -3.88), IL-6 (SMD = -10.59), IL-1β (SMD = -3.98), TNF-α (SMD = -8.05), NF-κB (SMD = -5.46), TLR4 (MD = -0.38), RORγ (MD = -0.89), MCP-1 (MD = -153.25), MPO (SMD = -7.34), Caspase-9 (MD = -0.93), Caspase-3 (MD = -0.45), FasL (MD = -1.20)) and enhanced BWC (MD = 0.06), CL (MD = 1.39), ZO-1 (MD = 0.44), SOD (SMD = 3.04), IL-10 mRNA (MD = 3.14), and FOXP3 (MD = 0.45) levels. Baicalin’s actions may involve the PI3K/AKT, TLR4/NF-κB, IKK/IKB, Bcl-2/Bax, Th17/Treg, and TLRs/MyD88 pathways. Optimal therapeutic outcomes were predicted at dosages of 60–150 mg/kg over 10–14 weeks. Conclusion Baicalin demonstrates a multifaceted therapeutic potential in UC, attributed to its anti-inflammatory, antioxidant, anti-apoptotic, and intestinal barrier repair properties. While higher doses and longer treatments appear beneficial, further research, particularly human clinical trials, is necessary to verify its effectiveness and safety in people.https://doi.org/10.1186/s12876-025-03629-0BaicalinUlcerative colitisAnimal modelMeta-analysisSystematic review |
| spellingShingle | Jinchen Chong Zepeng Chen Jiaze Ma Linhai He Yijia Zhu Zhihua Lu Zhengxi Qiu Chen Chen Yugen Chen Feng Jiang Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis BMC Gastroenterology Baicalin Ulcerative colitis Animal model Meta-analysis Systematic review |
| title | Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis |
| title_full | Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis |
| title_fullStr | Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis |
| title_full_unstemmed | Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis |
| title_short | Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis |
| title_sort | mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis a preclinical systematic review and meta analysis |
| topic | Baicalin Ulcerative colitis Animal model Meta-analysis Systematic review |
| url | https://doi.org/10.1186/s12876-025-03629-0 |
| work_keys_str_mv | AT jinchenchong mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT zepengchen mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT jiazema mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT linhaihe mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT yijiazhu mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT zhihualu mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT zhengxiqiu mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT chenchen mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT yugenchen mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis AT fengjiang mechanisticinvestigationandtheoptimaldosebasedonbaicalininthetreatmentofulcerativecolitisapreclinicalsystematicreviewandmetaanalysis |